Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)
Identifieur interne : 001978 ( Main/Exploration ); précédent : 001977; suivant : 001979Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)
Auteurs : Josef S. Smolen [Autriche] ; Joel M. Kremer [États-Unis] ; Carol L. Gaich [États-Unis] ; Amy M. Delozier [États-Unis] ; Douglas E. Schlichting [États-Unis] ; Li Xie [États-Unis] ; Ivaylo Stoykov [États-Unis] ; Terence Rooney [États-Unis] ; Paul Bird [Australie] ; Juan Miguel Sánchez Burs N [Espagne] ; Mark C. Genovese [États-Unis] ; Bernard Combe [France]Source :
- Annals of the Rheumatic Diseases [ 0003-4967 ] ; 2016.
Descripteurs français
- KwdFr :
- Adulte, Azétidines (usage thérapeutique), Enquêtes et questionnaires, Humains, Indice de gravité médicale, Inhibiteurs de protéines kinases (usage thérapeutique), Jeune adulte, Mesure de la douleur, Mesures des résultats rapportés par les patients, Méthode en double aveugle, Polyarthrite rhumatoïde (), Polyarthrite rhumatoïde (traitement médicamenteux), Présentéisme, Qualité de vie, Rendement, Sulfonamides (usage thérapeutique).
- MESH :
- traitement médicamenteux : Polyarthrite rhumatoïde.
- usage thérapeutique : Azétidines, Inhibiteurs de protéines kinases, Sulfonamides.
- Adulte, Enquêtes et questionnaires, Humains, Indice de gravité médicale, Jeune adulte, Mesure de la douleur, Mesures des résultats rapportés par les patients, Méthode en double aveugle, Polyarthrite rhumatoïde, Présentéisme, Qualité de vie, Rendement.
English descriptors
- KwdEn :
- Adult, Arthritis, Rheumatoid (complications), Arthritis, Rheumatoid (drug therapy), Azetidines (therapeutic use), Double-Blind Method, Efficiency, Humans, Pain Measurement, Patient Reported Outcome Measures, Presenteeism, Protein Kinase Inhibitors (therapeutic use), Quality of Life, Severity of Illness Index, Sulfonamides (therapeutic use), Surveys and Questionnaires, Young Adult.
- MESH :
- chemical , therapeutic use : Azetidines, Protein Kinase Inhibitors, Sulfonamides.
- complications : Arthritis, Rheumatoid.
- drug therapy : Arthritis, Rheumatoid.
- Adult, Double-Blind Method, Efficiency, Humans, Pain Measurement, Patient Reported Outcome Measures, Presenteeism, Quality of Life, Severity of Illness Index, Surveys and Questionnaires, Young Adult.
Abstract
To assess baricitinib on patient-reported outcomes (PROs) in patients with moderately to severely active rheumatoid arthritis, who had insufficient response or intolerance to ≥1 tumour necrosis factor inhibitors (TNFis) or other biological disease-modifying antirheumatic drugs (bDMARDs).
In this double-blind phase III study, patients were randomised to once-daily placebo or baricitinib 2 or 4 mg for 24 weeks. PROs included the Short Form-36, EuroQol 5-D, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Health Assessment Questionnaire-Disability Index (HAQ-DI), Patient's Global Assessment of Disease Activity (PtGA), patient's assessment of pain, duration of morning joint stiffness (MJS) and Work Productivity and Activity Impairment Questionnaire-Rheumatoid Arthritis. Treatment comparisons were performed with logistic regression for categorical measures or analysis of covariance for continuous variables.
527 patients were randomised (placebo, 176; baricitinib 2 mg, 174; baricitinib 4 mg, 177). Both baricitinib-treated groups showed statistically significant improvements versus placebo in most PROs. Improvements were generally more rapid and of greater magnitude for patients receiving baricitinib 4 mg than 2 mg and were maintained to week 24. At week 24, more baricitinib-treated patients versus placebo-treated patients reported normal physical functioning (HAQ-DI <0.5; p≤0.001), reductions in fatigue (FACIT-F ≥3.56; p≤0.05), improvements in PtGA (p≤0.001) and pain (p≤0.001) and reductions in duration of MJS (p<0.01).
Baricitinib improved most PROs through 24 weeks compared with placebo in this study of treatment-refractory patients with previously inadequate responses to bDMARDs, including at least one TNFi. PRO results aligned with clinical efficacy data for baricitinib.
Url:
DOI: 10.1136/annrheumdis-2016-209821
PubMed: 27799159
PubMed Central: 5530360
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 002258
- to stream Pmc, to step Curation: 002108
- to stream Pmc, to step Checkpoint: 000718
- to stream PubMed, to step Corpus: 000E91
- to stream PubMed, to step Curation: 000E88
- to stream PubMed, to step Checkpoint: 000E88
- to stream Ncbi, to step Merge: 003D99
- to stream Ncbi, to step Curation: 003D99
- to stream Ncbi, to step Checkpoint: 003D99
- to stream Main, to step Merge: 001974
- to stream Main, to step Curation: 001978
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)</title><author><name sortKey="Smolen, Josef S" sort="Smolen, Josef S" uniqKey="Smolen J" first="Josef S" last="Smolen">Josef S. Smolen</name><affiliation wicri:level="1"><nlm:aff id="af1"><institution>Medical University of Vienna and Hietzing Hospital</institution>,<addr-line>Vienna</addr-line>,<country>Austria</country></nlm:aff><country xml:lang="fr">Autriche</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Kremer, Joel M" sort="Kremer, Joel M" uniqKey="Kremer J" first="Joel M" last="Kremer">Joel M. Kremer</name><affiliation wicri:level="1"><nlm:aff id="af2"><institution>Albany Medical College</institution>,<addr-line>Albany, New York</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Gaich, Carol L" sort="Gaich, Carol L" uniqKey="Gaich C" first="Carol L" last="Gaich">Carol L. Gaich</name><affiliation wicri:level="1"><nlm:aff id="af3"><institution>Eli Lilly and Company</institution>,<addr-line>Indianapolis, Indiana</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Delozier, Amy M" sort="Delozier, Amy M" uniqKey="Delozier A" first="Amy M" last="Delozier">Amy M. Delozier</name><affiliation wicri:level="1"><nlm:aff id="af3"><institution>Eli Lilly and Company</institution>,<addr-line>Indianapolis, Indiana</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Schlichting, Douglas E" sort="Schlichting, Douglas E" uniqKey="Schlichting D" first="Douglas E" last="Schlichting">Douglas E. Schlichting</name><affiliation wicri:level="1"><nlm:aff id="af3"><institution>Eli Lilly and Company</institution>,<addr-line>Indianapolis, Indiana</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Xie, Li" sort="Xie, Li" uniqKey="Xie L" first="Li" last="Xie">Li Xie</name><affiliation wicri:level="1"><nlm:aff id="af3"><institution>Eli Lilly and Company</institution>,<addr-line>Indianapolis, Indiana</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Stoykov, Ivaylo" sort="Stoykov, Ivaylo" uniqKey="Stoykov I" first="Ivaylo" last="Stoykov">Ivaylo Stoykov</name><affiliation wicri:level="1"><nlm:aff id="af3"><institution>Eli Lilly and Company</institution>,<addr-line>Indianapolis, Indiana</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Rooney, Terence" sort="Rooney, Terence" uniqKey="Rooney T" first="Terence" last="Rooney">Terence Rooney</name><affiliation wicri:level="1"><nlm:aff id="af3"><institution>Eli Lilly and Company</institution>,<addr-line>Indianapolis, Indiana</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Bird, Paul" sort="Bird, Paul" uniqKey="Bird P" first="Paul" last="Bird">Paul Bird</name><affiliation wicri:level="1"><nlm:aff id="af4"><institution>University of New South Wales</institution>,<addr-line>Sydney, New South Wales</addr-line>,<country>Australia</country></nlm:aff><country xml:lang="fr">Australie</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Sanchez Burs N, Juan Miguel" sort="Sanchez Burs N, Juan Miguel" uniqKey="Sanchez Burs N J" first="Juan Miguel" last="Sánchez Burs N">Juan Miguel Sánchez Burs N</name><affiliation wicri:level="1"><nlm:aff id="af5"><addr-line>Divisions of Rheumatology, Ophthalmology and Immunology</addr-line>,<institution>Valme University Hospital</institution>,<addr-line>Sevilla</addr-line>,<country>Spain</country></nlm:aff><country xml:lang="fr">Espagne</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Genovese, Mark C" sort="Genovese, Mark C" uniqKey="Genovese M" first="Mark C" last="Genovese">Mark C. Genovese</name><affiliation wicri:level="1"><nlm:aff id="af6"><institution>Stanford University Medical Center</institution>,<addr-line>Palo Alto, California</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Combe, Bernard" sort="Combe, Bernard" uniqKey="Combe B" first="Bernard" last="Combe">Bernard Combe</name><affiliation wicri:level="1"><nlm:aff id="af7"><institution>Lapeyronie Hospital, Montpellier University</institution>,<addr-line>Montpellier</addr-line>,<country>France</country></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">27799159</idno><idno type="pmc">5530360</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530360</idno><idno type="RBID">PMC:5530360</idno><idno type="doi">10.1136/annrheumdis-2016-209821</idno><date when="2016">2016</date><idno type="wicri:Area/Pmc/Corpus">002258</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">002258</idno><idno type="wicri:Area/Pmc/Curation">002108</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">002108</idno><idno type="wicri:Area/Pmc/Checkpoint">000718</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000718</idno><idno type="wicri:source">PubMed</idno><idno type="wicri:Area/PubMed/Corpus">000E91</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000E91</idno><idno type="wicri:Area/PubMed/Curation">000E88</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000E88</idno><idno type="wicri:Area/PubMed/Checkpoint">000E88</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000E88</idno><idno type="wicri:Area/Ncbi/Merge">003D99</idno><idno type="wicri:Area/Ncbi/Curation">003D99</idno><idno type="wicri:Area/Ncbi/Checkpoint">003D99</idno><idno type="wicri:doubleKey">0003-4967:2016:Smolen J:patient:reported:outcomes</idno><idno type="wicri:Area/Main/Merge">001974</idno><idno type="wicri:Area/Main/Curation">001978</idno><idno type="wicri:Area/Main/Exploration">001978</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)</title><author><name sortKey="Smolen, Josef S" sort="Smolen, Josef S" uniqKey="Smolen J" first="Josef S" last="Smolen">Josef S. Smolen</name><affiliation wicri:level="1"><nlm:aff id="af1"><institution>Medical University of Vienna and Hietzing Hospital</institution>,<addr-line>Vienna</addr-line>,<country>Austria</country></nlm:aff><country xml:lang="fr">Autriche</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Kremer, Joel M" sort="Kremer, Joel M" uniqKey="Kremer J" first="Joel M" last="Kremer">Joel M. Kremer</name><affiliation wicri:level="1"><nlm:aff id="af2"><institution>Albany Medical College</institution>,<addr-line>Albany, New York</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Gaich, Carol L" sort="Gaich, Carol L" uniqKey="Gaich C" first="Carol L" last="Gaich">Carol L. Gaich</name><affiliation wicri:level="1"><nlm:aff id="af3"><institution>Eli Lilly and Company</institution>,<addr-line>Indianapolis, Indiana</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Delozier, Amy M" sort="Delozier, Amy M" uniqKey="Delozier A" first="Amy M" last="Delozier">Amy M. Delozier</name><affiliation wicri:level="1"><nlm:aff id="af3"><institution>Eli Lilly and Company</institution>,<addr-line>Indianapolis, Indiana</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Schlichting, Douglas E" sort="Schlichting, Douglas E" uniqKey="Schlichting D" first="Douglas E" last="Schlichting">Douglas E. Schlichting</name><affiliation wicri:level="1"><nlm:aff id="af3"><institution>Eli Lilly and Company</institution>,<addr-line>Indianapolis, Indiana</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Xie, Li" sort="Xie, Li" uniqKey="Xie L" first="Li" last="Xie">Li Xie</name><affiliation wicri:level="1"><nlm:aff id="af3"><institution>Eli Lilly and Company</institution>,<addr-line>Indianapolis, Indiana</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Stoykov, Ivaylo" sort="Stoykov, Ivaylo" uniqKey="Stoykov I" first="Ivaylo" last="Stoykov">Ivaylo Stoykov</name><affiliation wicri:level="1"><nlm:aff id="af3"><institution>Eli Lilly and Company</institution>,<addr-line>Indianapolis, Indiana</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Rooney, Terence" sort="Rooney, Terence" uniqKey="Rooney T" first="Terence" last="Rooney">Terence Rooney</name><affiliation wicri:level="1"><nlm:aff id="af3"><institution>Eli Lilly and Company</institution>,<addr-line>Indianapolis, Indiana</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Bird, Paul" sort="Bird, Paul" uniqKey="Bird P" first="Paul" last="Bird">Paul Bird</name><affiliation wicri:level="1"><nlm:aff id="af4"><institution>University of New South Wales</institution>,<addr-line>Sydney, New South Wales</addr-line>,<country>Australia</country></nlm:aff><country xml:lang="fr">Australie</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Sanchez Burs N, Juan Miguel" sort="Sanchez Burs N, Juan Miguel" uniqKey="Sanchez Burs N J" first="Juan Miguel" last="Sánchez Burs N">Juan Miguel Sánchez Burs N</name><affiliation wicri:level="1"><nlm:aff id="af5"><addr-line>Divisions of Rheumatology, Ophthalmology and Immunology</addr-line>,<institution>Valme University Hospital</institution>,<addr-line>Sevilla</addr-line>,<country>Spain</country></nlm:aff><country xml:lang="fr">Espagne</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Genovese, Mark C" sort="Genovese, Mark C" uniqKey="Genovese M" first="Mark C" last="Genovese">Mark C. Genovese</name><affiliation wicri:level="1"><nlm:aff id="af6"><institution>Stanford University Medical Center</institution>,<addr-line>Palo Alto, California</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Combe, Bernard" sort="Combe, Bernard" uniqKey="Combe B" first="Bernard" last="Combe">Bernard Combe</name><affiliation wicri:level="1"><nlm:aff id="af7"><institution>Lapeyronie Hospital, Montpellier University</institution>,<addr-line>Montpellier</addr-line>,<country>France</country></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author></analytic><series><title level="j">Annals of the Rheumatic Diseases</title><idno type="ISSN">0003-4967</idno><idno type="eISSN">1468-2060</idno><imprint><date when="2016">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Arthritis, Rheumatoid (complications)</term><term>Arthritis, Rheumatoid (drug therapy)</term><term>Azetidines (therapeutic use)</term><term>Double-Blind Method</term><term>Efficiency</term><term>Humans</term><term>Pain Measurement</term><term>Patient Reported Outcome Measures</term><term>Presenteeism</term><term>Protein Kinase Inhibitors (therapeutic use)</term><term>Quality of Life</term><term>Severity of Illness Index</term><term>Sulfonamides (therapeutic use)</term><term>Surveys and Questionnaires</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Azétidines (usage thérapeutique)</term><term>Enquêtes et questionnaires</term><term>Humains</term><term>Indice de gravité médicale</term><term>Inhibiteurs de protéines kinases (usage thérapeutique)</term><term>Jeune adulte</term><term>Mesure de la douleur</term><term>Mesures des résultats rapportés par les patients</term><term>Méthode en double aveugle</term><term>Polyarthrite rhumatoïde ()</term><term>Polyarthrite rhumatoïde (traitement médicamenteux)</term><term>Présentéisme</term><term>Qualité de vie</term><term>Rendement</term><term>Sulfonamides (usage thérapeutique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Azetidines</term><term>Protein Kinase Inhibitors</term><term>Sulfonamides</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Arthritis, Rheumatoid</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Arthritis, Rheumatoid</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Polyarthrite rhumatoïde</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Azétidines</term><term>Inhibiteurs de protéines kinases</term><term>Sulfonamides</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Double-Blind Method</term><term>Efficiency</term><term>Humans</term><term>Pain Measurement</term><term>Patient Reported Outcome Measures</term><term>Presenteeism</term><term>Quality of Life</term><term>Severity of Illness Index</term><term>Surveys and Questionnaires</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Enquêtes et questionnaires</term><term>Humains</term><term>Indice de gravité médicale</term><term>Jeune adulte</term><term>Mesure de la douleur</term><term>Mesures des résultats rapportés par les patients</term><term>Méthode en double aveugle</term><term>Polyarthrite rhumatoïde</term><term>Présentéisme</term><term>Qualité de vie</term><term>Rendement</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Objectives</title><p>To assess baricitinib on patient-reported outcomes (PROs) in patients with moderately to severely active rheumatoid arthritis, who had insufficient response or intolerance to ≥1 tumour necrosis factor inhibitors (TNFis) or other biological disease-modifying antirheumatic drugs (bDMARDs).</p></sec><sec><title>Methods</title><p>In this double-blind phase III study, patients were randomised to once-daily placebo or baricitinib 2 or 4 mg for 24 weeks. PROs included the Short Form-36, EuroQol 5-D, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Health Assessment Questionnaire-Disability Index (HAQ-DI), Patient's Global Assessment of Disease Activity (PtGA), patient's assessment of pain, duration of morning joint stiffness (MJS) and Work Productivity and Activity Impairment Questionnaire-Rheumatoid Arthritis. Treatment comparisons were performed with logistic regression for categorical measures or analysis of covariance for continuous variables.</p></sec><sec><title>Results</title><p>527 patients were randomised (placebo, 176; baricitinib 2 mg, 174; baricitinib 4 mg, 177). Both baricitinib-treated groups showed statistically significant improvements versus placebo in most PROs. Improvements were generally more rapid and of greater magnitude for patients receiving baricitinib 4 mg than 2 mg and were maintained to week 24. At week 24, more baricitinib-treated patients versus placebo-treated patients reported normal physical functioning (HAQ-DI <0.5; p≤0.001), reductions in fatigue (FACIT-F ≥3.56; p≤0.05), improvements in PtGA (p≤0.001) and pain (p≤0.001) and reductions in duration of MJS (p<0.01).</p></sec><sec><title>Conclusions</title><p>Baricitinib improved most PROs through 24 weeks compared with placebo in this study of treatment-refractory patients with previously inadequate responses to bDMARDs, including at least one TNFi. PRO results aligned with clinical efficacy data for baricitinib.</p></sec><sec><title>Trial registration number</title><p><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01721044">NCT01721044</ext-link>; Results.</p></sec></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Carr, A" uniqKey="Carr A">A Carr</name></author><author><name sortKey="Hewlett, S" uniqKey="Hewlett S">S Hewlett</name></author><author><name sortKey="Hughes, R" uniqKey="Hughes R">R Hughes</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Strand, V" uniqKey="Strand V">V Strand</name></author><author><name sortKey="Cohen, S" uniqKey="Cohen S">S Cohen</name></author><author><name sortKey="Crawford, B" uniqKey="Crawford B">B Crawford</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Klarenbeek, Nb" uniqKey="Klarenbeek N">NB Klarenbeek</name></author><author><name sortKey="Guler Yuksel, M" uniqKey="Guler Yuksel M">M Güler-Yüksel</name></author><author><name sortKey="Van Der Kooij, Sm" uniqKey="Van Der Kooij S">SM van der Kooij</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Drossaers Bakker, Kw" uniqKey="Drossaers Bakker K">KW Drossaers-Bakker</name></author><author><name sortKey="De Buck, M" uniqKey="De Buck M">M de Buck</name></author><author><name sortKey="Van Zeben, D" uniqKey="Van Zeben D">D van Zeben</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Aletaha, D" uniqKey="Aletaha D">D Aletaha</name></author><author><name sortKey="Smolen, J" uniqKey="Smolen J">J Smolen</name></author><author><name sortKey="Ward, Mm" uniqKey="Ward M">MM Ward</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Smolen, Js" uniqKey="Smolen J">JS Smolen</name></author><author><name sortKey="Aletaha, D" uniqKey="Aletaha D">D Aletaha</name></author><author><name sortKey="Grisar, Jc" uniqKey="Grisar J">JC Grisar</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Aletaha, D" uniqKey="Aletaha D">D Aletaha</name></author><author><name sortKey="Strand, V" uniqKey="Strand V">V Strand</name></author><author><name sortKey="Smolen, Js" uniqKey="Smolen J">JS Smolen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Aletaha, D" uniqKey="Aletaha D">D Aletaha</name></author><author><name sortKey="Ward, Mm" uniqKey="Ward M">MM Ward</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Smolen, Js" uniqKey="Smolen J">JS Smolen</name></author><author><name sortKey="Aletaha, D" uniqKey="Aletaha D">D Aletaha</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Smolen, Js" uniqKey="Smolen J">JS Smolen</name></author><author><name sortKey="Landewe, R" uniqKey="Landewe R">R Landewé</name></author><author><name sortKey="Breedveld, Fc" uniqKey="Breedveld F">FC Breedveld</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Singh, Ja" uniqKey="Singh J">JA Singh</name></author><author><name sortKey="Saag, Kg" uniqKey="Saag K">KG Saag</name></author><author><name sortKey="Bridges, Sl" uniqKey="Bridges S">SL Bridges</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sanderson, T" uniqKey="Sanderson T">T Sanderson</name></author><author><name sortKey="Morris, M" uniqKey="Morris M">M Morris</name></author><author><name sortKey="Calnan, M" uniqKey="Calnan M">M Calnan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gossec, L" uniqKey="Gossec L">L Gossec</name></author><author><name sortKey="Dougados, M" uniqKey="Dougados M">M Dougados</name></author><author><name sortKey="Dixon, W" uniqKey="Dixon W">W Dixon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Aletaha, D" uniqKey="Aletaha D">D Aletaha</name></author><author><name sortKey="Landewe, R" uniqKey="Landewe R">R Landewe</name></author><author><name sortKey="Karonitsch, T" uniqKey="Karonitsch T">T Karonitsch</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="O Shea, Jj" uniqKey="O Shea J">JJ O'Shea</name></author><author><name sortKey="Holland, Sm" uniqKey="Holland S">SM Holland</name></author><author><name sortKey="Staudt, Lm" uniqKey="Staudt L">LM Staudt</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Genovese, Mc" uniqKey="Genovese M">MC Genovese</name></author><author><name sortKey="Kremer, J" uniqKey="Kremer J">J Kremer</name></author><author><name sortKey="Zamani, O" uniqKey="Zamani O">O Zamani</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Brazier, Je" uniqKey="Brazier J">JE Brazier</name></author><author><name sortKey="Harper, R" uniqKey="Harper R">R Harper</name></author><author><name sortKey="Jones, Nm" uniqKey="Jones N">NM Jones</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ware, Je" uniqKey="Ware J">JE Ware</name></author><author><name sortKey="Sherbourne, Cd" uniqKey="Sherbourne C">CD Sherbourne</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Strand, V" uniqKey="Strand V">V Strand</name></author><author><name sortKey="Singh, Ja" uniqKey="Singh J">JA Singh</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kosinski, M" uniqKey="Kosinski M">M Kosinski</name></author><author><name sortKey="Zhao, Sz" uniqKey="Zhao S">SZ Zhao</name></author><author><name sortKey="Dedhiya, S" uniqKey="Dedhiya S">S Dedhiya</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Brooks, R" uniqKey="Brooks R">R Brooks</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Herdman, M" uniqKey="Herdman M">M Herdman</name></author><author><name sortKey="Gudex, C" uniqKey="Gudex C">C Gudex</name></author><author><name sortKey="Lloyd, A" uniqKey="Lloyd A">A Lloyd</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cella, D" uniqKey="Cella D">D Cella</name></author><author><name sortKey="Yount, S" uniqKey="Yount S">S Yount</name></author><author><name sortKey="Sorensen, M" uniqKey="Sorensen M">M Sorensen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Strand, V" uniqKey="Strand V">V Strand</name></author><author><name sortKey="Burmester, Gr" uniqKey="Burmester G">GR Burmester</name></author><author><name sortKey="Zerbini, Ca" uniqKey="Zerbini C">CA Zerbini</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Keystone, E" uniqKey="Keystone E">E Keystone</name></author><author><name sortKey="Burmester, Gr" uniqKey="Burmester G">GR Burmester</name></author><author><name sortKey="Furie, R" uniqKey="Furie R">R Furie</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bruce, B" uniqKey="Bruce B">B Bruce</name></author><author><name sortKey="Fries, Jf" uniqKey="Fries J">JF Fries</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ramey, Dr" uniqKey="Ramey D">DR Ramey</name></author><author><name sortKey="Fries, Jf" uniqKey="Fries J">JF Fries</name></author><author><name sortKey="Singh, G" uniqKey="Singh G">G Singh</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wells, Ga" uniqKey="Wells G">GA Wells</name></author><author><name sortKey="Tugwell, P" uniqKey="Tugwell P">P Tugwell</name></author><author><name sortKey="Kraag, Gr" uniqKey="Kraag G">GR Kraag</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Reilly, Mc" uniqKey="Reilly M">MC Reilly</name></author><author><name sortKey="Zbrozek, As" uniqKey="Zbrozek A">AS Zbrozek</name></author><author><name sortKey="Dukes, Em" uniqKey="Dukes E">EM Dukes</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Navarro Compan, V" uniqKey="Navarro Compan V">V Navarro-Compán</name></author><author><name sortKey="Smolen, Js" uniqKey="Smolen J">JS Smolen</name></author><author><name sortKey="Huizinga, Twj" uniqKey="Huizinga T">TWJ Huizinga</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Felson, Dt" uniqKey="Felson D">DT Felson</name></author><author><name sortKey="Anderson, Jj" uniqKey="Anderson J">JJ Anderson</name></author><author><name sortKey="Boers, M" uniqKey="Boers M">M Boers</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Strand, V" uniqKey="Strand V">V Strand</name></author><author><name sortKey="Burmester, Gr" uniqKey="Burmester G">GR Burmester</name></author><author><name sortKey="Ogale, S" uniqKey="Ogale S">S Ogale</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Westhovens, R" uniqKey="Westhovens R">R Westhovens</name></author><author><name sortKey="Cole, Jc" uniqKey="Cole J">JC Cole</name></author><author><name sortKey="Li, T" uniqKey="Li T">T Li</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Smolen, Js" uniqKey="Smolen J">JS Smolen</name></author><author><name sortKey="Kay, J" uniqKey="Kay J">J Kay</name></author><author><name sortKey="Doyle, Mk" uniqKey="Doyle M">MK Doyle</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Strand, V" uniqKey="Strand V">V Strand</name></author><author><name sortKey="Smolen, Js" uniqKey="Smolen J">JS Smolen</name></author><author><name sortKey="Van Vollenhoven, Rf" uniqKey="Van Vollenhoven R">RF van Vollenhoven</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Keystone, Ec" uniqKey="Keystone E">EC Keystone</name></author><author><name sortKey="Genovese, Mc" uniqKey="Genovese M">MC Genovese</name></author><author><name sortKey="Klareskog, L" uniqKey="Klareskog L">L Klareskog</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Burmester, Gr" uniqKey="Burmester G">GR Burmester</name></author><author><name sortKey="Blanco, R" uniqKey="Blanco R">R Blanco</name></author><author><name sortKey="Charles Schoeman, C" uniqKey="Charles Schoeman C">C Charles-Schoeman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Keystone, Ec" uniqKey="Keystone E">EC Keystone</name></author><author><name sortKey="Van Der Heijde, D" uniqKey="Van Der Heijde D">D van der Heijde</name></author><author><name sortKey="Kavanaugh, A" uniqKey="Kavanaugh A">A Kavanaugh</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Genovese, Mc" uniqKey="Genovese M">MC Genovese</name></author><author><name sortKey="Schiff, M" uniqKey="Schiff M">M Schiff</name></author><author><name sortKey="Luggen, M" uniqKey="Luggen M">M Luggen</name></author></analytic></biblStruct></listBibl></div1></back></TEI><affiliations><list><country><li>Australie</li><li>Autriche</li><li>Espagne</li><li>France</li><li>États-Unis</li></country></list><tree><country name="Autriche"><noRegion><name sortKey="Smolen, Josef S" sort="Smolen, Josef S" uniqKey="Smolen J" first="Josef S" last="Smolen">Josef S. Smolen</name></noRegion></country><country name="États-Unis"><noRegion><name sortKey="Kremer, Joel M" sort="Kremer, Joel M" uniqKey="Kremer J" first="Joel M" last="Kremer">Joel M. Kremer</name></noRegion><name sortKey="Delozier, Amy M" sort="Delozier, Amy M" uniqKey="Delozier A" first="Amy M" last="Delozier">Amy M. Delozier</name><name sortKey="Gaich, Carol L" sort="Gaich, Carol L" uniqKey="Gaich C" first="Carol L" last="Gaich">Carol L. Gaich</name><name sortKey="Genovese, Mark C" sort="Genovese, Mark C" uniqKey="Genovese M" first="Mark C" last="Genovese">Mark C. Genovese</name><name sortKey="Rooney, Terence" sort="Rooney, Terence" uniqKey="Rooney T" first="Terence" last="Rooney">Terence Rooney</name><name sortKey="Schlichting, Douglas E" sort="Schlichting, Douglas E" uniqKey="Schlichting D" first="Douglas E" last="Schlichting">Douglas E. Schlichting</name><name sortKey="Stoykov, Ivaylo" sort="Stoykov, Ivaylo" uniqKey="Stoykov I" first="Ivaylo" last="Stoykov">Ivaylo Stoykov</name><name sortKey="Xie, Li" sort="Xie, Li" uniqKey="Xie L" first="Li" last="Xie">Li Xie</name></country><country name="Australie"><noRegion><name sortKey="Bird, Paul" sort="Bird, Paul" uniqKey="Bird P" first="Paul" last="Bird">Paul Bird</name></noRegion></country><country name="Espagne"><noRegion><name sortKey="Sanchez Burs N, Juan Miguel" sort="Sanchez Burs N, Juan Miguel" uniqKey="Sanchez Burs N J" first="Juan Miguel" last="Sánchez Burs N">Juan Miguel Sánchez Burs N</name></noRegion></country><country name="France"><noRegion><name sortKey="Combe, Bernard" sort="Combe, Bernard" uniqKey="Combe B" first="Bernard" last="Combe">Bernard Combe</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001978 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001978 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= PMC:5530360
|texte= Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27799159" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |